pemvidutide vs semaglutide Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study Safety and efficacy of 24

Staying hydrated is simple but often overlooked

Those with government-funded insurance plans like Medicare or Medicaid are not eligible for the Savings Card

The SURMOUNT trial program involved large, diverse populations

Factor consumers at different stages of usage into demand forecasts for supplements, fitness services, and wellness products

Researchers from the German Center for Diabetes Research (DZD) and Helmholtz Munich, in collaboration with a colleague from the University of Santiago de Compostela in Spain, describe the development of incretin-based pharmacotherapy from its beginnings to the discovery of polyagonists